Navigation Links
Revenue Growth Optimism in Pharmaceutical Industry: 2013 Survey Reports at

DALLAS, Feb. 19, 2013 /PRNewswire-iReach/ -- Overall, as per the global pharmaceutical industry survey on buyer spend and procurement strategies, 55% of respondents are 'more optimistic' about revenue growth for their companies in 2013, due to success in clinical trials, approval and acceptance from drug authorities, an increase in expenditure from governments and a surge in sales, all of which are projected to increase the profitability of pharmaceutical manufacturing companies in 2013. The top three key expected changes for 2013 are development of new products and services, improvement of operational efficiency and 'expansion in current markets'.


Among emerging markets, China is identified as the most important region for pharmaceutical industry growth, along with Brazil and India. Presence of huge and aging population, economic development, growing public expenditure towards healthcare, government support, increasing awareness about health and fitness in public are key drivers for the growth of the pharmaceutical market in China.

Developed pharmaceutical markets such as Singapore, Taiwan, Hong Kong, the US, and South Korea are also identified as important regions for growth in 2013. The availability of a skilled workforce and the presence of logistics support, which increases connectivity to target markets within the region, positions Singapore as a strategically important link within the South-East Asia region. Moreover, Singapore acts as a significant trading base for the South-East Asian region, with low corporate taxes and strong intellectual property rights attracting companies to setup their operations in Singapore. The world's largest pharmaceutical market, the US, is expected to register minimal growth over the next five years; however, beyond 2015, a higher number of people will be insured in the US, resulting in increased drug consumption.

Executives from the global pharmaceutical industry expect to see increased levels of consolidation, with 61% of respondents anticipating either a significant increase or an increase in M&A activity in 2013. The need for new product pipelines, new product acquisition, patent expiries, cost containment, and credit availability are identified as the key drivers for increase in M&A activities in the global pharmaceutical industry. Larger companies have cash piled in their accounts books, while their product line is limited to few market leading products. These companies find it as an opportunity to acquire and leverage on promising portfolios from smaller organizations.

Buy the report "Global Pharmaceutical Survey 2013-2014 – Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" at; and the report "Global Pharmaceutical Survey 2013-2014 – Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry" at

Reasons to buy one or more of these reports with their key features and benefits:

  • Projects industry trends and revenue growth expectations in 2013, and understand business confidence to make informed business decisions.
  • Drive revenues by understanding future product investment areas and key growth regions.
  • Uncover key challenges and opportunities and identify key actions required to maintain and win buyer business.
  • Formulate effective sales and marketing strategies by identifying the overall size of the marketing budgets of global pharmaceutical industry supplier companies. Also, how buyer budgets are changing and the direction of spending in the future. Better promote your business by aligning your capabilities and business practices with your customer's changing needs.
  • Identifies the key marketing aims of organizations and which sales strategies companies will be adopting to deal with market conditions in 2013-2014.
  • Secure stronger customer relationships by understanding the behaviour and changing strategies of industry buyers.

Explore more reports on the Pharmaceuticals Industry @

About Us: is an online market research reports library of 175,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore other market reports online as well as Company Profiles and SWOT Analysis Reports of companies in multiple sectors @

Media Contact: Priyank Tiwari, RnR Market Research, + 1 888 391 5441,

News distributed by PR Newswire iReach:

SOURCE RnRMarketResearch
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
2. Medical Marijuana, Inc. Releases 2012 Annual Share Holders Report and First Ever Corporate Revenue Forecasts
3. CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
4. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
5. Mesa Labs Reports 18% Increase in Third Quarter Revenues
6. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
7. Abaxis Reports Record Revenues For The Third Quarter Of Fiscal 2013
8. Haemonetics Reports 3rd Quarter Fiscal 2013 Revenue Up 29% and $0.50 Adjusted EPS; Year-To-Date Organic Revenue Up 3%; Reaffirms Fiscal 2013 Adjusted EPS Guidance of $1.65-$1.70
9. Glenmarks Consolidated Revenue Increases by 33.96% to Rs. 13812.59 Million for Q3 FY 12-13
10. Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
11. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):